08:47 AM EDT, 05/30/2024 (MT Newswires) -- Numinus Wellness Inc. ( NUMIF ) , a mental health care company, said Thursday that it has received approval from Health Canada for a clinical trial application to assess the feasibility of a group model in MDMA-assisted psychotherapy enrolling trainee practitioners as participants.

The purpose of the study is to determine the ideal number of therapists needed to administer MDMA-assisted psychotherapy group sessions.

"Considering the growing body of research into the potential benefits of MDMA for treating severe mental disorders, such as PTSD, it's essential that medical professionals enhance their understanding of how best to administer it in a clinical environment," Payton Nyquvest, Numinus founder and CEO, said.

The clinical trial is titled "Phase 1 Exploration of Feasibility and Optimal Therapist Numbers in Group Model MDM-Assisted Psychotherapy: A Study on Safety, Delivery, and Practitioner Training."